Gentian Diagnostics ASA has unveiled promising findings from its latest research at EuroMedLab 2025 in Brussels. The company presented two scientific posters focusing on innovative diagnostic assays. The NT-proBNP assay, currently in development, introduces a novel approach to heart failure detection by targeting glycosylation-free regions of the NT-proBNP molecule. This approach aims to provide more accurate assessments by overcoming glycosylation bias, which traditionally hampers antibody binding. The Gentian proto-type assay demonstrated strong analytical performance and compatibility with major instrument platforms, such as Mindray and Beckman Coulter. Meanwhile, the Retinol-Binding Protein (RBP) assay focuses on nutritional status evaluation and renal function assessment. The study established a comprehensive reference range using the Beckman Coulter DxC 700 AU Analyzer, highlighting RBP's dual role as a biomarker for vitamin A deficiency and renal dysfunction. Gentian's research emphasizes the importance of assay-specific validation to ensure accurate clinical interpretation, marking significant advancements in diagnostic workflows.